Sugi Predict

Sugi Predict / Compounds / SCHEMBL365201

SCHEMBL365201

SCHEMBL365201

O=C1OCc2cc(F)ccc21

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.61
▸ LMNA P02545 2/20 0.61
▸ GAA P10253 1/20 0.61
▸ MAOA P21397 7/20 0.59
▸ MAOB P27338 7/20 0.59
▸ PRF1 P14222 4/20 0.54
▸ RECQL P46063 1/20 0.54
▸ ALDH1A1 P00352 3/20 0.53
▸ IMPDH2 P12268 1/20 0.49
▸ KCNJ1 P48048 1/20 0.49
▸ KCNH2 Q12809 1/20 0.49
▸ CYP3A4 P08684 1/20 0.46
▸ PPIA P62937 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31621082 1.00 MAPT (0.61) MAPTLMNAGAAMAOAMAOB
SCHEMBL30132801 0.84 MAOB (0.62) MAPTLMNAGAAMAOAMAOB
SCHEMBL856120 0.84 MAOB (0.62) MAPTLMNAGAAMAOAMAOB
SCHEMBL25386333 0.83 MAOB (0.54) MAPTLMNAGAAMAOAMAOB
SCHEMBL13932273 0.81 SRD5A1 (0.44) MAPTLMNAGAAMAOAMAOB
SCHEMBL25386767 0.80 MAOB (0.61) MAPTLMNAGAAMAOAMAOB
SCHEMBL31470976 0.80 MAOB (0.61) MAPTLMNAGAAMAOAMAOB
SCHEMBL4043697 0.78 MAPK14 (0.56) —
SCHEMBL14559426 0.78 MAPK14 (0.60) MAPTGAAMAOAMAOBALDH1A1
SCHEMBL10554226 0.77 ALDH1A1 (0.53) MAPTGAAMAOAMAOBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114276319-B Synthesis method of loratidine intermediate 滁州学院 2023-11-03 — — CN claimed
CN-114276319-A Synthetic method of Laolatinib intermediate 滁州学院 2022-04-05 — — CN claimed
CN-109134410-B Synthesis method of 5-fluoro-3-methylisobenzofuran-1 (3H) -ketone 沈阳药科大学 2022-03-25 — — CN claimed
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 — — WO disclosed
US-12600733-B2 KRAS inhibitors ELI LILLY AND COMPANY (US) 2026-04-14 — — US disclosed
US-20260092075-A1 KRAS INHIBITORS LILLY CO ELI (US) 2026-04-02 — — US disclosed
US-20260055097-A9 NRF2 PROTEIN DEGRADERS GANYMEDE ONCOLOGY INC (US) 2026-02-26 — — US disclosed
EP-4688784-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2026-02-11 — — EP disclosed
EP-4688792-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2026-02-11 — — EP disclosed
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENT OF THE UNIV OF MICHIGAN (US) 2026-01-29 — — US disclosed
US-20260007681-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS UNIV MICHIGAN (US) 2026-01-08 — — US disclosed
CN-1503795-A Water-soluble triazole antifungal agents ������������ʽ���� 2004-06-09 — — CN disclosed
EP-1362856-A1 WATER-SOLUBLE TRIAZOLE FUNGICIDE Sankyo Company, Limited (JP) 2003-11-19 — — EP disclosed
US-20030199494-A1 1,2,3,5-tetrahydrobenzo'c!azepin-4-one derivatives having muscarinic antagonist activity MUSCAGEN LIMITED (GB) 2003-10-23 — — US disclosed
EP-1294697-A1 1,2,3,5-TETRAHYDROBENZO[C]AZEPIN-4-ONE DERIVATIVES HAVING MUSCARINIC ANTAGONIST ACTIVITY Muscagen Limited (GB) 2003-03-26 — — EP disclosed
EP-1194419-A1 METHOD FOR PRODUCING 2-HETEROCYCLYL METHYL BENZOIC ACID DERIVATIVES Bayer Aktiengesellschaft (DE) 2002-04-10 — — EP disclosed
WO-2002006241-A1 1, 2, 3, 5 -TETRAHYDROBENZO`C!AZEPIN-4-ONE DERIVATIVES HAVING MUSCARINIC ANTAGONIST ACTIVITY MUSCAGEN LIMITED (GB) 2002-01-24 — — WO disclosed
WO-2001000595-A1 METHOD FOR PRODUCING 2-HETEROCYCLYL METHYL BENZOIC ACID DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2001-01-04 — — WO disclosed
US-4889858-A ANTIHYPOXIC AGENTS, ANTICONVULSANTS, LIPID PEROXIDATION INHIBITORS DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1989-12-26 — — US disclosed
EP-0269755-A1 DIBENZ b,e OXEPIN DERIVATIVE AND PHARMACEUTICAL CONTAINING THE SAME AS ACTIVE INGREDIENT Dainippon Pharmaceutical Co., Ltd. (JP) 1988-06-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600733-B2 KRAS inhibitors KRAS, NRAS, HRAS MAPT 4756/4885LMNA 2137/4885GAA 4327/4885
US-20030199494-A1 1,2,3,5-tetrahydrobenzo'c!azepin-4-one derivatives having muscarinic antagonist activity CHRM1, CHRM3, CHRM2 MAPT 4062/4885LMNA 3871/4885GAA 4759/4885
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, ESRRB MAPT 4305/4885LMNA 2007/4885GAA 4291/4885
US-20260007681-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, AR MAPT 4310/4885LMNA 3179/4885GAA 4539/4885
US-20260092075-A1 KRAS INHIBITORS KRAS, NRAS, HRAS MAPT 4836/4885LMNA 2418/4885GAA 3911/4885
US-20260055097-A9 NRF2 PROTEIN DEGRADERS KEAP1, NFE2L2, NFE2 MAPT 3815/4885LMNA 901/4885GAA 2839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.